New Production Facility to Support the Manufacturing Monoclonal Antibodies (mAbs)
New Production Facility to Support the Manufacturing Monoclonal Antibodies (mAbs)
Our customer a leading pharmaceutical manufacturer needed to increase the production capacity of monoclonal antibodies as bio-pharmaceutical drug substance using mammalian cell cultures. As a result, a new greenfield facility plant of 25’000 m2 was planned in Singapore.
Key Results
- Delivery of a over 25’000 m2 greenfield facility
- Area lead responsibility – for upstream, buffer & media preparation, CIP, laboratories, clean media
- Integrated superskid approach resulted in accelerated schedule
- Delivery of both fixed and disposable technologies
- Intelligent coordination of 3D models
Key Project Features
- State of the art concept plan
- Modular process and automation design
- Flexible QC laboratory and small scale disposable design
- Innovative materials warehousing solution
- Superskid vendor coordination through design, construction and installation
- International project coordination
Our Delivery
- Collaborative concept design with the client team with particular focus on HSE protection in the handling of highly active API’s
- Feasibility, basic and detailed process design, laboratory and clean utilities design.
- Lead teams of contractors through the design, commissioning and qualification process
- Vendor presence during superskid construction process
- Fully modular concept allowing installation of two further bioreactor trains and additional DSP line
- Coordinated vendor and main plant 3D models
Value to Our Customer
- Delivery of a greenfield, state of the art production facility
- Innovative skid and superskid approach
- Modular technology
- Innovative, lean laboratory process design allowed integration of the laboratory into the main production building
